JP2025512373A - 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 - Google Patents

多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 Download PDF

Info

Publication number
JP2025512373A
JP2025512373A JP2024560278A JP2024560278A JP2025512373A JP 2025512373 A JP2025512373 A JP 2025512373A JP 2024560278 A JP2024560278 A JP 2024560278A JP 2024560278 A JP2024560278 A JP 2024560278A JP 2025512373 A JP2025512373 A JP 2025512373A
Authority
JP
Japan
Prior art keywords
subscript
integer
seq
subscripts
sum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024560278A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025512373A5 (https=
Inventor
エム.ジャクソン ウェスリー
エー.トゥワイト エイミー
バーネベイ アダム
ウィルツ ブライアー リビア
Original Assignee
バリター,インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バリター,インコーポレイティド filed Critical バリター,インコーポレイティド
Publication of JP2025512373A publication Critical patent/JP2025512373A/ja
Publication of JP2025512373A5 publication Critical patent/JP2025512373A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114Kunitz type inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241Tumor Necrosis Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2318/00Antibody mimetics or scaffolds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024560278A 2022-04-15 2023-04-14 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法 Pending JP2025512373A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263331554P 2022-04-15 2022-04-15
US63/331,554 2022-04-15
PCT/US2023/065779 WO2023201337A2 (en) 2022-04-15 2023-04-14 Method of treating uveitis with multivalent protein-hyaluronic acid polymer conjugate

Publications (2)

Publication Number Publication Date
JP2025512373A true JP2025512373A (ja) 2025-04-17
JP2025512373A5 JP2025512373A5 (https=) 2026-04-21

Family

ID=88330394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024560278A Pending JP2025512373A (ja) 2022-04-15 2023-04-14 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法

Country Status (7)

Country Link
US (1) US20250255972A1 (https=)
EP (1) EP4507731A2 (https=)
JP (1) JP2025512373A (https=)
KR (1) KR20250005285A (https=)
AU (1) AU2023252928A1 (https=)
CA (1) CA3256208A1 (https=)
WO (1) WO2023201337A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202602849A (zh) * 2024-03-28 2026-01-16 日商日產化學股份有限公司 石墨烯連接化合物及場效電晶體生物檢測器

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220251185A1 (en) * 2019-07-01 2022-08-11 Valitor, Inc. Hydrophilic linkers for multivalent peptide conjugates

Also Published As

Publication number Publication date
WO2023201337A2 (en) 2023-10-19
WO2023201337A3 (en) 2023-11-23
CA3256208A1 (en) 2023-10-19
AU2023252928A1 (en) 2024-10-24
KR20250005285A (ko) 2025-01-09
EP4507731A2 (en) 2025-02-19
US20250255972A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
JP7736577B2 (ja) 多価ペプチドコンジュゲート用の親水性リンカー
JP2021521111A (ja) カンプトテシンペプチドコンジュゲート
CN116271079B (zh) 一种抗dll3抗体及其制备方法、其药物偶联物和应用
JP2022550851A (ja) カンプトテシンペプチドコンジュゲート
US20130259882A1 (en) Conjugate of Folate and Antibody Preparation Method and Use Thereof
HRP20050353A2 (en) Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
CN103282055A (zh) 抗糖尿病化合物
US20180371060A1 (en) Modified pigment epithelium-derived factor (pedf) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
CN109069581B (zh) 锁环螺旋肽及合成方法
JP2025512373A (ja) 多価タンパク質-ヒアルロン酸ポリマーコンジュゲートを用いてぶどう膜炎を治療する方法
US20230405133A1 (en) Purified multivalent protein-hyaluronic acid polymer conjugates
EP2496262A2 (en) Stabilized protein formulations and use thereof
CN115702004A (zh) 具有cd3和cd19双重特异性的聚乙二醇化t细胞衔接器
TW202220700A (zh) 包含三重升糖素/glp-1/gip受體促效劑的長效接合物的醫藥組成物
US20230406916A1 (en) Humanized multivalent protein conjugates
RU2855513C1 (ru) Фармацевтическая композиция, содержащая длительно действующий конъюгат тройного агониста рецепторов глюкагона/GLP-1/GIP
US20260097125A1 (en) Ultra-long-acting platform comprising fc-advanced fatty acid chain
KR102177339B1 (ko) 경구용 유전자 전달체 및 이의 용도
HK40129608A (en) Ultra-long-acting platform comprising fc-advanced fatty acid chain
HK40101829A (zh) 免疫调节抗体药物结合物
HK1189606A (en) Conjugate of folate and antibody, preparation method and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260413

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260413